Combination of | |
---|---|
Trandolapril | Calcium channel blocker |
Verapamil | ACE inhibitor |
Clinical data | |
Trade names | Tarka |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
KEGG |
Trandolapril/verapamil (Tarka)[2] is an oral antihypertensive medication that combines a slow release formulation of verapamil hydrochloride, a calcium channel blocker, and an immediate release formulation of trandolapril, an ACE inhibitor. The patent, held by Abbott Laboratories, expired on February 24, 2015.
This combination medication contains angiotensin-converting enzyme (ACE) inhibitor and calcium channel blocker and is prescribed for high blood pressure.[3][4][5]